2009
- 18 December 2009
Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications - 11 December 2009
Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia - 07 December 2009
Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients with Acute Myeloid Leukemia at ASH Conference - 29 November 2009
New Performance Upgrades From Zonare Medical Systems Deliver Premium Image Quality And Expanded Applications For Z.one Ultrasound Platform - 19 November 2009
Wellpartner Teams with Sea Mar Community Health Center to Offer Access to Affordable Medications - 05 November 2009
Wellpartner Teams with Klamath Open Door Clinic to Offer Access to Affordable Medications - 03 November 2009
Triage Wireless, Inc. Becomes Sotera Wireless, Inc. - 03 November 2009
Wellpartner Teams with Community Health Centers of Lane County to Offer Access to Affordable Medications - 27 October 2009
Leading Independent Fostering Company By the Bridge Receives Debt Financing from Clydesdale Bank - 20 October 2009
Zonare Ranked No 3 Fastest Growing Company in Silicon Valley by the Silicon Valley Business Journal - 13 October 2009
CancerPartnerUK Brings New-World Class Radiotherapy to Portsmouth - 18 September 2009
Wyeth and Ambrx Form Multi-target Alliance to Leverage Recent Ambrx Biologics Platform Advances - 16 September 2009
Ulthera Receives First-Ever FDA Clearance to Market Ultrasound Technology for Facial Improvement - 10 August 2009
Baptist Health System Installs Seven Z.one Ultrasound Systems from Zonare Medical Systems - 30 July 2009
OmniGuide Featured in BioOptics World: Flexible CO2 Fiber Tackles Inoperable Conditions - 28 July 2009
Zonare Begins Customer Shipments of the Z.one Ultra SP System - 1 July 2009
Wellpartner Featured in Oregon Business as One of the Fastest Growing Companies in Oregon, USA - 14 May 2009
Anaphore, Inc. Announces $13 Million Second Closing to Series A Financing - 7 April 2009
Serentis Starts Phase II Trial with First-in-Class SRD441 for Eczema - 5 March 2009
CancerPartners UK Starts Construction of New-State-Of-Art Regional Cancer Centre - 4 March 2009
Serentis Starts Phase II Clinical Trial in Pruritus of Skin Disease - 24 February 2009
Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance - 23 February 2009
Pharmakodex Acquired by Leading Swedish Pharmaceutical Company, Orexo - 7 January 2009
Anaphore, Inc. Announces $25 million Series A Financing